Company News

2022-05-17
The Phase Ib/II clinical study of IMM01 combined with PD-1 antibody in the treatment of relapsed and refractory malignant tumors completed the first patient enrollment and administration
On May 17, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the FPI in the Phase Ib/II clinical study of first domestic SIRPα-Fc fusion protein targeting human CD47 (project number: IMM01) combined with PD-1 antibody for relapsed and refractory malignant tumors (clinical research project number: IMM01-04). The first subject was enrolled and dosed successfully.
View more
2022-04-01
ImmuneOnco Announced Appointment of Dr. Xiaodong Gan as Senior Vice President for Clinical trials
On April 1, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Frank Xiaodong Gan was appointed as the senior vice president of our Company in April 2022, and is responsible for clinical development of our Group in the United States.
View more
2022-03-30
ImmuneOnco Announced Appointment of Dr. Xu, Wencheng as Vice President of Clinical Operations
On March 30, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Xu, Wencheng as the vice president of clinical operations.
View more
2022-03-28
ImmuneOnco will share data in two posters at 2022 Annual Meeting of American Association for Cancer Research(AACR)
On March 28, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that data from 2 different new projects in two posters will be presented at the 2022 annual meeting of American Association for Cancer Research (AACR) hold in New Orleans from April 8 to 13.
View more
2022-03-21
Dr. Lu, Qiying joined ImmuneOnco as Chief Medical Officer (CMO) and Senior Vice President (SVP)
On March 21, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared the appointment of Dr. Lu Qiying was appointed as the chief medical officer and senior vice president of our Company in March 2022, and is responsible for formulating the clinical strategy and direct clinical development of our Group.
View more
2022-03-15
Dr. Xiong, Zikai joined ImmuneOnco as Senior Vice President(SVP)
On March 15, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Xiong Zikai as the senior vice president (SVP) to be fully responsible for the company's BD affairs.
View more
Total 55 12345678910
0.088916s